Streetbeat News

Analyst Ratings

FMC

Blue Orca Capital has issued a short report on FMC Corporation, highlighting undisclosed legal setbacks and the impact of generic competition on its revenues. FMC's revenues have already been hit by a global oversupply of inventory, and a 30% Y/Y decline was reported recently. The report suggests that FMC misled investors about the potential for generic competition for its flagship diamides. Legal rulings have allowed generic alternatives to enter key markets in India and China, with Brazil likely to follow. These generics are often sold at significantly lower prices, threatening FMC's market share.

Portfolio Pulse from Vandana Singh

September 07, 2023 | 3:18 pm

VXRT

Vaxart Inc has released topline data from the Phase 2 challenge study of its oral tablet monovalent norovirus vaccine candidate, showing a statistically significant 29% reduction in the rate of norovirus infection between the vaccinated and placebo arms. The study also showed an 85% decrease in viral shedding in the vaccine arm compared with placebo. Vaxart is currently conducting additional analyses of the data from this challenge study and its prior norovirus trials to define the timing of a larger Phase 2b study. VXRT shares are down 6.56% at $0.75 on the last check Thursday.

Portfolio Pulse from Vandana Singh

September 07, 2023 | 3:13 pm

KVUE

A significant amount of unusual options activity has been observed for Kenvue (NYSE:KVUE), indicating a bullish stance by a large investor or institution. The overall sentiment of these big-money traders is split between 51% bullish and 48% bearish. The volume of KVUE is down -3.84% at $21.52. The next earnings are expected to be released in 62 days.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 3:02 pm

MU

16 analysts have provided ratings for Micron Technology (NASDAQ:MU) over the last quarter, with an average price target of $74.75, indicating an upside from the current price of $70.17. The average price target has increased by 17.25% from the previous average of $63.75.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 3:00 pm

OSTK

Over the past quarter, Overstock.com (NASDAQ:OSTK) has received a mix of bullish and indifferent ratings from analysts. The average price target is $48.0, which is significantly higher than the current price of $19.425. However, this represents a 4.0% decrease from the previous average price target of $50.00.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 3:00 pm

APTO

Aptose Biosciences (NASDAQ:APTO) has received mostly bullish ratings from analysts in the last quarter, with an average price target of $27.75, a high of $50.00, and a low of $12.00. This average price target has increased by 17.04% over the past month.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 3:00 pm

TGT

Over the past 3 months, 28 analysts have published their opinion on Target (NYSE:TGT) stock. The average price target is $154.11, implying an upside from the current price of $124.4. This average represents a 8.72% decrease from the previous average price target of $168.83.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 3:00 pm

SAGE

Sage Therapeutics (NASDAQ:SAGE) has received mixed analyst ratings in the last quarter, with 1 bullish, 2 somewhat bullish, and 15 indifferent ratings. The average 12-month price target for the company is $30.28, a 44.69% decrease from the previous average of $54.75.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 3:00 pm

FATE

Fate Therapeutics (NASDAQ:FATE) has received mixed analyst ratings in the last quarter, with 1 bullish, 1 somewhat bullish, and 4 indifferent ratings. The average 12-month price target for the stock, according to 6 analysts, is $6.4, a decrease of 26.18% from the previous average of $8.67.

Portfolio Pulse from Benzinga Insights

September 07, 2023 | 3:00 pm

PHR

Phreesia, Inc. (NYSE:PHR) reported weaker-than-expected Q2 earnings, with a loss of 68 cents per share, wider than the expected loss of 42 cents per share. The company's sales were $85.83 million, slightly above estimates of $85.22 million. Phreesia's FY24 revenue forecast is $353 million to $356 million, close to estimates of $355.27 million. Following the earnings announcement, several analysts revised their price targets for Phreesia, leading to a 17.6% dip in the company's shares to $25.00.

Portfolio Pulse from Lisa Levin

September 07, 2023 | 3:00 pm